Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 1Meningioma 1Medulloblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoid Tumor 1

Interventions

Hydroxyurea 4aldesleukin 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Everolimus 3Temozolomide 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Proton Therapy 2Paclitaxel 2Laser Speckle Contrast Imaging 2Filgrastim 2Donepezil 2Cyclophosphamide 2Carmustine 2Bortezomib 2Bevacizumab 2Aminolevulinic Acid 290Y-octreotide, DOTA-Tyr(3)- 2vistusertib 1vatalanib 1trametinib 1tozuleristide 1temsirolimus 1sonidegib 1sargramostim 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Meningioma × arginyllysine × Clear all
NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡